Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Combinatorial Chemistry & High Throughput Screening
  4. Fast Track Articles
  5. Fast Track Article
image of Antiproliferative Activity of Cephalotaxus Esters: Overcoming Chemoresistance

Abstract

Introduction

Omacetaxine, a semisynthetic form of Homoharringtonine (HHT), was approved for the treatment of Chronic Myeloid Leukemia (CML). Previously, we have published the synthesis of this natural alkaloid and three of its derivatives: Deoxyharringtonine (DHT), Deoxyhomoharringtonine (DHHT), and Bis(demethyl)-deoxyharringtonine (BDHT), and reported its refractory activity against the HL-60/RV+ cells over-expressing P-glycoprotein 1 (MDR1).

Methods

In this study, we have explored the extent of this resistance by first expanding the panel of established cell lines and using a panel of 21 leukemia patient-derived primary cells.

Results

Herein, we have reported consistent resistance to HTT of K562-derived cells and to mitoxantrone of MES-SA/MX2-derived cells; all of them have been found to overexpress MDR1, while we have found U87MG-ABCG2 and H69AR cells to be very sensitive to HTT. In contrast, DHT, DHHT, and BDHT seemingly overcame this resistance due to the changes made to the acyl chain of HTT, rendering the derivatives less susceptible to efflux. Surprisingly, the leukemia primary cells were very sensitive to HHT and its derivatives with low nanomolar potencies, followed by a new class of CDC7 kinase inhibitors, the anthracycline class of topoisomerase inhibitors, the DNA intercalator actinomycin-D, and the vinca alkaloid class of microtubule inhibitors. The mechanism of cell death induced by HTT and DHHT was found to be mediated caspase 3 cleavage, leading to apoptosis.

Conclusion

Taken together, our results confirm that HHT is a substrate for MDR1. It opens the door to a new opportunity to clinically evaluate HHT and its derivatives for the treatment of AML and other cancers.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cchts/10.2174/0113862073322175240823104921
2024-10-23
2024-11-26

  • From This Site

    /content/journals/cchts/10.2174/0113862073322175240823104921
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Pérard-Viret J. Quteishat L. Alsalim R. Royer J. Dumas F. Cephalotaxus Alkaloids. Alkaloids Chem. Biol. 2017 78 205 352 10.1016/bs.alkal.2017.07.001 28838429
    [Google Scholar]
  2. Powell R.G. Weisleder D. Smith C.R. Jr Rohwedder W.K. Structures of harringtonine, isoharringtonine, and homoharringtonine. Tetrahedron Lett. 1970 11 11 815 818 10.1016/S0040‑4039(01)97839‑6 5436615
    [Google Scholar]
  3. Fresno M. Jiménez A. Vázquez D. Inhibition of translation in eukaryotic systems by harringtonine. Eur. J. Biochem. 1977 72 2 323 330 10.1111/j.1432‑1033.1977.tb11256.x 319998
    [Google Scholar]
  4. Gürel G. Blaha G. Moore P.B. Steitz T.A. U2504 determines the species specificity of the A-site cleft antibiotics: The structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J. Mol. Biol. 2009 389 1 146 156 10.1016/j.jmb.2009.04.005 19362093
    [Google Scholar]
  5. Huang M.T. Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol. Pharmacol. 1975 11 5 511 519 1237080
    [Google Scholar]
  6. Robert F. Carrier M. Rawe S. Chen S. Lowe S. Pelletier J. Altering chemosensitivity by modulating translation elongation. PLoS One 2009 4 5 e5428 10.1371/journal.pone.0005428 19412536
    [Google Scholar]
  7. Powell R.G. Weisleder D. Smith C.R. Jr Antitumor alkaloids for Cephalataxus harringtonia: Structure and activity. J. Pharm. Sci. 1972 61 8 1227 1230 10.1002/jps.2600610812 5050371
    [Google Scholar]
  8. Kantarjian H.M. Talpaz M. Santini V. Murgo A. Cheson B. O’Brien S.M. Homoharringtonine. Cancer 2001 92 6 1591 1605 10.1002/1097‑0142(20010915)92:6<1591::AID‑CNCR1485>3.0.CO;2‑U 11745238
    [Google Scholar]
  9. Feldman E.J. Seiter K.P. Ahmed T. Baskind P. Arlin Z.A. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia 1996 10 1 40 42 8558935
    [Google Scholar]
  10. O’Brien S. Kantarjian H. Keating M. Beran M. Koller C. Robertson L.E. Hester J. Rios M.B. Andreeff M. Talpaz M. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995 86 9 3322 3326 10.1182/blood.V86.9.3322.bloodjournal8693322 7579434
    [Google Scholar]
  11. O’Brien S. Kantarjian H. Koller C. Feldman E. Beran M. Andreeff M. Giralt S. Cheson B. Keating M. Freireich E. Rios M.B. Talpaz M. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 1999 93 12 4149 4153 10.1182/blood.V93.12.4149 10361112
    [Google Scholar]
  12. O’Brien S. Talpaz M. Cortes J. Shan J. Giles F.J. Faderl S. Thomas D. Garcia-Manero G. Mallard S. Beth Rios M. Koller C. Kornblau S. Andreeff M. Murgo A. Keating M. Kantarjian H.M. Simultaneous homoharringtonine and interferon‐α in the treatment of patients with chronic‐phase chronic myelogenous leukemia. Cancer 2002 94 7 2024 2032 10.1002/cncr.10436 11932905
    [Google Scholar]
  13. Feldman E. Arlin Z. Ahmed T. Mittelman A. Puccio C. Chun H. Cook P. Baskind P. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia 1992 6 11 1185 1188 1434802
    [Google Scholar]
  14. Feldman E. Arlin Z. Ahmed T. Mittelman A. Puccio C. Chun H. Cook P. Baskind P. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Leukemia 1992 6 11 1189 1191 1434803
    [Google Scholar]
  15. Covelli A. Modulation of multidrug resistance (MDR) in hematological malignancies. Ann. Oncol. 1999 10 Suppl. 6 S53 S60 10.1093/annonc/10.suppl_6.S53 10676553
    [Google Scholar]
  16. Choi Y. Yu A.M. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr. Pharm. Des. 2014 20 5 793 807 10.2174/138161282005140214165212 23688078
    [Google Scholar]
  17. Sharom F.J. ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 2008 9 1 105 127 10.2217/14622416.9.1.105 18154452
    [Google Scholar]
  18. Russo D. Michelutti A. Melli C. Damiani D. Michieli M.G. Candoni A. Zhou D.C. Marie J.P. Zittoun R. Baccarani M. MDR-related P170-glycoprotein modulates cytotoxic activity of homoharringtonine. Leukemia 1995 9 3 513 516 7885049
    [Google Scholar]
  19. Eckelbarger J.D. Wilmot J.T. Epperson M.T. Thakur C.S. Shum D. Antczak C. Tarassishin L. Djaballah H. Gin D.Y. Synthesis of antiproliferative Cephalotaxus esters and their evaluation against several human hematopoietic and solid tumor cell lines: Uncovering differential susceptibilities to multidrug resistance. Chemistry 2008 14 14 4293 4306 10.1002/chem.200701998 18366032
    [Google Scholar]
  20. Zhou D.C. Ramond S. Viguie F. Faussat A.M. Zittoun R. Marie J.P. Sequential emergence ofMRP- andMDR1-gene over-expression as well asMDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines. Int. J. Cancer 1996 65 3 365 371 10.1002/(SICI)1097‑0215(19960126)65:3<365::AID‑IJC15>3.0.CO;2‑9 8575859
    [Google Scholar]
  21. Nijhawan D. Fang M. Traer E. Zhong Q. Gao W. Du F. Wang X. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev. 2003 17 12 1475 1486 10.1101/gad.1093903 12783855
    [Google Scholar]
  22. Ma L. Krishnamachary N. Perbal B. Center M.S. HL-60 cells isolated for resistance to vincristine are defective in 12-O-tetradecanoylphorbol-13-acetate induced differentiation and the formation of a functional AP-1 complex. Oncol. Res. 1992 4 7 291 298 1450490
    [Google Scholar]
  23. Harker W.G. Slade D.L. Dalton W.S. Meltzer P.S. Trent J.M. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res. 1989 49 16 4542 4549 2568172
    [Google Scholar]
  24. Monville C. Fages C. Feyens A.M. d’Hondt V. Guillet C. Vernallis A. Gascan H. Peschanski M. Astroglial expression of the P-glycoprotein is controlled by intracellular CNTF. BMC Cell Biol. 2002 3 1 20 29 10.1186/1471‑2121‑3‑20 12150717
    [Google Scholar]
  25. Antczak C. Wee B. Radu C. Bhinder B. Holland E.C. Djaballah H. A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells. Assay Drug Dev. Technol. 2014 12 1 28 42 10.1089/adt.2013.521 23992118
    [Google Scholar]
  26. Wee B. Pietras A. Ozawa T. Bazzoli E. Podlaha O. Antczak C. Westermark B. Nelander S. Uhrbom L. Forsberg-Nilsson K. Djaballah H. Michor F. Holland E.C. ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells. Sci. Rep. 2016 6 1 25956 10.1038/srep25956 27456282
    [Google Scholar]
  27. Mirski S.E. Gerlach J.H. Cole S.P. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res. 1987 47 10 2594 2598 2436751
    [Google Scholar]
  28. Cole S.P.C. Chanda E.R. Dicke F.P. Gerlach J.H. Mirski S.E. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: Evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res. 1991 51 13 3345 3352 1675932
    [Google Scholar]
  29. Nazha A. Kantarjian H. Cortes J. Quintás-Cardama A. Omacetaxine mepesuccinate (synribo) – newly launched in chronic myeloid leukemia. Expert Opin. Pharmacother. 2013 14 14 1977 1986 10.1517/14656566.2013.821464 23875628
    [Google Scholar]
  30. Miller T.P. Grogan T.M. Dalton W.S. Spier C.M. Scheper R.J. Salmon S.E. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J. Clin. Oncol. 1991 9 1 17 24 10.1200/JCO.1991.9.1.17 1670642
    [Google Scholar]
  31. Chabner B.A. Fojo A. Multidrug resistance: P-glycoprotein and its allies--the elusive foes. J. Natl. Cancer Inst. 1989 81 12 910 913 10.1093/jnci/81.12.910 2567356
    [Google Scholar]
  32. Shum D. Santos R. Djaballah H. High-throughput profiling of leukemia cells for the identification of novel chemical scaffold signatures predicting disease-specific sensitivities. Cancer Res. 2007 67 9 Suppl. 5560
    [Google Scholar]
  33. Frattini M.G. Djaballah H. CDC7 kinase inhibitors and uses thereof. US Patent US009782386B2 2010
  34. Ross D.D. Novel mechanisms of drug resistance in leukemia. Leukemia 2000 14 3 467 473 10.1038/sj.leu.2401694 10720143
    [Google Scholar]
  35. Abolhoda A. Wilson A.E. Ross H. Danenberg P.V. Burt M. Scotto K.W. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin. Cancer Res. 1999 5 11 3352 3356 10589744
    [Google Scholar]
  36. Gottesman M.M. Fojo T. Bates S.E. Multidrug resistance in cancer: Role of ATP–dependent transporters. Nat. Rev. Cancer 2002 2 1 48 58 10.1038/nrc706 11902585
    [Google Scholar]
  37. Efferth T. Sauerbrey A. Halatsch M.E. Ross D.D. Gebhart E. Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines. Naunyn Schmiedebergs Arch. Pharmacol. 2003 367 1 56 67 10.1007/s00210‑002‑0632‑0 12616342
    [Google Scholar]
  38. Tang R. Faussat A.M. Majdak P. Marzac C. Dubrulle S. Marjanovic Z. Legrand O. Marie J.P. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol. Cancer Ther. 2006 5 3 723 731 10.1158/1535‑7163.MCT‑05‑0164 16546987
    [Google Scholar]
  39. Chen R. Guo L. Chen Y. Jiang Y. Wierda W.G. Plunkett W. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood 2011 117 1 156 164 10.1182/blood‑2010‑01‑262808 20971952
    [Google Scholar]
  40. Chen R. Gandhi V. Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res. 2006 66 22 10959 10966 10.1158/0008‑5472.CAN‑06‑1216 17108134
    [Google Scholar]
/content/journals/cchts/10.2174/0113862073322175240823104921
Loading
Antiproliferative Activity of Cephalotaxus Esters: Overcoming Chemoresistance
Bentham Science Publishers ; https://doi.org/10.2174/0113862073322175240823104921
/content/journals/cchts/10.2174/0113862073322175240823104921
/content/journals/cchts/10.2174/0113862073322175240823104921
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: leukemia ; MDR ; CML ; Cancer ; natural products ; AML ; homoharringtonine ; drug resistance

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test